Strides Sustainability Report for FY25.

Strides Pharma Science has submitted its second consecutive Sustainability Report for FY25 (April 2024 to March 2025), prepared under the Global Reporting Initiative (GRI) Standards 2021 and aligned with SASB, UN Global Compact, UN SDGs, and SEBI's BRSR framework. In its debut participation in S&P Global's Corporate Sustainability Assessment, the company scored 75, placing it in the top 10% of companies across all industries worldwide. Key highlights include 42.65% of energy from renewable sources, commitment to Science Based Targets (SBTi) for emissions reduction, biodiversity risk assessments at Bengaluru and Puducherry plants, and Life Cycle Assessment for its Macrogol product. On the social side, the company supplied 2.4 billion doses of anti-malaria medication across 60+ countries since 2013 and 800 billion doses of HIV medication across 26+ countries since 2020. Governance metrics include 100% employee training in Code of Conduct, 62.5% independent directors on the Board with 40% women representation among independents, and expansion of the Risk Management Committee's scope to include sustainability oversight.